Clinical trial NCT01184274: A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia
Official title: A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Leukemia
Solid Tumours
Lead sponsor: Canadian Cancer Trials Group
Sponsor class: NETWORK
Collaborators: name: S*BIO
First posted: 2010-08-18
Enrollment: 12
Sex: ALL
Minimum age (years): 12
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This research is being done because SB939 has been shown to shrink tumours in animals and in some people and seems promising, but we are not sure if it can offer better results than standard treatment.

Detailed description: In Part A of this study, SB939 was given to children with solid tumours. The purpose of Part A of this study is to ind the highest dose of a new drug SB939 that can be giben to children without causing very severe side effects that are tolerable.

In Part B of this study, SB939 will be given to children with leukemia. The purpose of Part B, is to see whether the dose that was determined to be the best dose for patients with solid tumours is also the best dose for children with leukemia.

In Part C of this study, SB939 will be given together with 13-cis-retinoic acid. The purpose of Part C, is to see whether the SB939 dose that was determined to be the best dose in Part A is also the best dose when given in combination with 13-cis-retinoic acid.

Eligibility criteria: Inclusion Criteria:

* Patients in all parts of the study must have histological verification of malignancy at either original diagnosis or relapse.

  * For Part A, patients must have recurrent or refractory solid tumours, lymphoma or CNS tumours (excluding diffuse intrinsic pontine gliomas).
  * For Part B, patients must have recurrent or refractory leukemia.
  * For Part C, patients must have one of the following diagnoses: neuroblastoma, or medulloblastoma / CNS primitive neuroectodermal tumour (PNET).

Disease Status

* Patients with solid tumours must have either measurable or evaluable disease (defined by a positive nuclear scan such as bone scan or metaiodobenzylguanidine (MIBG) scan. For part C only, in the case of neuroblastoma, if a lesion is isolated and /or previously irradiated and stable, a proven positive biopsy will be required to be eligible.
* Patients with refractory or relapsed leukemia must have greater than 25% blasts in bone marrow (M3 bone marrow); active extramedullary disease may also be present. Patients with leptomeningeal disease are not eligible.

Therapeutic Options:

The patient's current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life.

Prior Systemic Therapy

Patients must have recovered from the acute effects of prior chemotherapy, immunotherapy or radiotherapy prior to study entry as follows:

* At least 3 weeks from completion of myelosuppressive chemotherapy, biologic agents or other investigational cancer treatment
* At least 7 days from completion of therapy with a growth factor
* At least 6 weeks from hematopoietic stem cell rescue following myeloablative therapy
* Post allogeneic hematopoietic transplant patients are eligible, but must have no evidence of active graft vs. host disease
* At least 2 weeks from completion of local palliative XRT (small port)
* At least 3 months must have elapsed if prior total body irradiation, craniospinal XRT or if ≥ 50% radiation of pelvis
* At least 6 weeks must have elapsed if other substantial bone marrow irradiation
* At least 6 weeks from prior MIBG therapy Age \> 12 months and ≤ 18 years at the time of study entry. Performance Status: Karnofsky ≥ 60% for patients \> 10 years; Lansky ≥ 50 for patients ≤ 10 years.

For Patients with Solid Tumours (Parts A and C):

* Absolute neutrophil count (ANC) ≥ 1.0 x 10 (power of 9)/L
* Platelets ≥100 x 10(power of 9)/L
* Hemoglobin ≥ 80 g/L

For Patients with Leukemia (Part B only)

* No minimum absolute neutrophil count
* Platelet count ≥ 20 x 10 (power of 9)/L (may receive transfusion)
* Hemoglobin ≥ 80 g/L (may receive transfusion)
* serum creatinine ≤ 1. 5 x upper limit of normal for age or
* measured GFR ≥ 70 mL/min/1.73 m2
* LVEF by ECHO or MUGA Scan within normal institutional limits
* QTc ≤ 450 msec

  * AST and ALT ≤ 5.0 x upper limit normal for age
  * bilirubin ≤ 1.5 x upper limit normal for age

Additional Criteria For Part C Of The Study

* Skin toxicity (excluding alopecia) ≤ Grade 1
* Serum triglycerides (fasting) \< 3.4 mmol/L
* Negative urine dipstick for protein OR \< 1000 mg protein/24 hour urine collection
* No evidence of gross hematuria

Patient or guardian consent must be obtained on all patients according to local Institutional and/or University Human Experimentation Committee requirements.

Patients registered on this trial must be treated and followed at the participating centre.

Protocol treatment to begin within five working days of patient registration.

Exclusion Criteria:

* Cardiac Exclusions. Patients with a pathologic cardiac arrhythmia requiring active treatment. Patients with a history of arrhythmia must be \> 12 months since last treatment with no recurrence of arrhythmia in the interval.
* Inability To Take Oral Medication. Patients must be able to take oral medication and have no gastrointestinal abnormalities (e.g. bowel obstruction or previous gastric resection) which would lead to inadequate absorption of SB939.
* Known HIV, hepatitis B or hepatitis C infections.
* Current treatment with agents with a known risk of Torsades de Pointes http://torsades.org (list #1).
* Pre-existing peripheral neuropathy ≥ grade 3.
* There is no available information regarding human fetal or teratogenic toxicities related to SB939. 13-cis-retinoic acid is known to be teratogenic. Pregnancy tests must be obtained in girls who are post menarchal. Males or females of reproductive potential may not participate unless they have agreed to an effective contraceptive method. Pregnant or breast feeding females will not be entered on this study due to the potential fetal and teratogenic adverse events.

Primary outcomes:
measure: Part A: Maximum Tolerated Dose and RP2D in solid tumours
timeFrame: 24 months
measure: Part B: Tolerability
timeFrame: 24 months
measure: Part C: Recommended Phase 2 Dose (RP2D) and Tolerability
timeFrame: 24 months
measure: Pharmacokinetics
timeFrame: 24 months
Secondary outcomes:
measure: Anti-tumour activity
timeFrame: 24 months
Other outcomes:
Locations:
city: Calgary
country: Canada
facility: Alberta Children's Hospital
state: Alberta
city: Edmonton
country: Canada
facility: Stollery Children's Hospital
state: Alberta
city: Vancouver
country: Canada
facility: Children's and Women's Health Centre of BC Branch
state: British Columbia
city: Winnipeg
country: Canada
facility: CancerCare Manitoba
state: Manitoba
city: Halifax
country: Canada
facility: Izaak Walton Killam (IWK) Health Centre
state: Nova Scotia
city: Ottawa
country: Canada
facility: Children's Hospital of Eastern Ontario
state: Ontario
city: Toronto
country: Canada
facility: Hospital for Sick Children
state: Ontario
city: Montreal
country: Canada
facility: CHU Sainte-Justine
state: Quebec
Study officials:
affiliation: Hospital for Sick Children, Toronto Ontario Canada
name: Sylvain Baruchel
role: STUDY_CHAIR
References:
citation: Zorzi AP, Bernstein M, Samson Y, Wall DA, Desai S, Nicksy D, Wainman N, Eisenhauer E, Baruchel S. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium. Pediatr Blood Cancer. 2013 Nov;60(11):1868-74. doi: 10.1002/pbc.24694. Epub 2013 Jul 25.